Key terms
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RXRX news
Apr 12
8:11pm ET
Cathie Wood’s ARK Investment buys 372K shares of Recursion Pharmaceuticals today
Apr 09
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
Apr 01
8:17pm ET
Cathie Wood’s ARK Investment bought 834K shares of Recursion Pharmaceuticals
Mar 26
9:04pm ET
Cathie Wood’s ARK Investment bought 733K shares of Recursion Pharmaceuticals
Mar 14
11:05am ET
Recursion Pharmaceuticals call volume above normal and directionally bullish
Mar 13
12:05pm ET
Recursion Pharmaceuticals call volume above normal and directionally bullish
Mar 11
5:10am ET
Recursion Pharmaceuticals to open new office in London in June
Mar 08
11:25am ET
Recursion Pharmaceuticals call volume above normal and directionally bullish
Mar 01
1:08am ET
Recursion Pharmaceuticals: A Hold Rating Amidst Promising Collaborations and Anticipatory Financial Health Review
Feb 28
6:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Feb 27
8:10pm ET
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Arcutis Biotherapeutics (ARQT)
Feb 27
4:38pm ET
Recursion Pharmaceuticals reports Q4 EPS (42c), consensus (45c)
Feb 27
4:23pm ET
Recursion Pharmaceuticals Enhances Investor Communication Strategy
Feb 27
2:34pm ET
Recursion Pharmaceuticals options imply 14.8% move in share price post-earnings
Feb 15
7:22am ET
SoundHound, Nano-X Imaging jump after Nvidia details holdings
Feb 13
8:07pm ET
Cathie Wood’s ARK Investment bought 519K shares of Recursion Pharmaceuticals
Feb 08
5:03am ET
Recursion Pharmaceuticals Restructures Executive Leadership Team
Feb 05
8:05pm ET
Cathie Wood’s ARK Investment bought 204K shares of Recursion Pharmaceuticals
Jan 26
9:33am ET
Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
Jan 26
7:25am ET
Recursion Pharmaceuticals initiated with a Market Perform at TD Cowen
Jan 26
5:45am ET
Recursion Pharmaceuticals: Hold Rating with a Focus on Strategic Execution and Upcoming Milestones
Jan 24
8:06pm ET
Cathie Wood’s ARK Investment bought 282.6K shares of Recursion Pharmaceuticals
Jan 24
12:04pm ET
Nvidia (NASDAQ:NVDA) Brings Supercomputing-as-a-Service To Life
Jan 23
8:04pm ET
Cathie Wood’s ARK Investment bought 251K shares of Recursion Pharmaceuticals
Jan 18
9:25pm ET
Cathie Wood’s ARK Investment bought 528K shares of Recursion Pharmaceuticals
Jan 17
8:06pm ET
Cathie Wood’s ARK Investment bought 633K shares of Recursion Pharmaceuticals
Jan 16
8:05pm ET
Cathie Wood’s ARK Investment bought 413K shares of Recursion Pharmaceuticals
No recent press releases are available for RXRX
RXRX Financials
Key terms
Ad Feedback
RXRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RXRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
